|
Sep 21
|
Rhythm Pharmaceuticals, Inc. (RYTM): Short Seller Sentiment is Bearish
|
|
Sep 18
|
Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 7.4% Jump Turn into More Strength?
|
|
Aug 28
|
Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More
|
|
Aug 27
|
High Growth Tech Stocks To Watch In August 2024
|
|
Aug 26
|
Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old
|
|
Aug 26
|
Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September
|
|
Jul 23
|
Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity
|
|
Jul 23
|
Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
|
|
May 8
|
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2024 Earnings Call Transcript
|
|
May 8
|
Rhythm Pharmaceuticals Inc (RYTM) Q1 2024 Earnings Call Transcript Highlights: A Detailed ...
|
|
May 8
|
Q1 2024 Rhythm Pharmaceuticals Inc Earnings Call
|
|
May 7
|
The 3 Best Nasdaq Stocks to Buy in May 2024
|
|
May 7
|
Rhythm Pharmaceuticals Reports Q1 2024 Results: Revenue Growth Amidst Challenges
|
|
May 7
|
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
|
|
May 6
|
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
|
|
May 1
|
Will Amicus Therapeutics (FOLD) Report Negative Q1 Earnings? What You Should Know
|
|
Apr 30
|
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Expected to Decline
|
|
Apr 29
|
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
|
|
Apr 24
|
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
|
|
Apr 14
|
Market Sentiment Around Loss-Making Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
|